Johnson & Johnson unveiled its second atopic dermatitis-focused deal this month on 28 May, paying $1.25bn in cash to acquire a subsidiary of Numab Therapeutics AG that houses a Phase II-ready bispecific antibody that J&J thinks will offer a novel approach to addressing two distinct disease-driving pathways in AD.
J&J Continues Atopic Dermatitis Effort With Numab Deal
Johnson & Johnson, after several prior failed R&D attempts in AD, will pay Numab $1.25bn to acquire a subsidiary and its Phase II-ready bispecific antibody for key unmet needs in the disease.
More from Deals
• By
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
More from Business
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.